
Glenmark Pharmaceuticals Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 3- US business: Expected to strengthen in coming years with new product filings (e.g., Fluticasone MDI filing planned between Q4 and Q1) and respiratory product launches; however, near-term outlook uncertain due to market conditions.
- Europe and Rest of World (ROW): Strong, broad-based growth expected; Europe targeting 15-20% minimum growth with further margin expansion; ROW (including Asia, Latin America, Middle East, Africa) performing well with key approvals driving growth (e.g., in Brazil, Russia).
- India: Anticipated sustained growth of 12-15% over the next three years, driven by RX (respiratory, cardiac, dermatology, diabetes segments), OTC, and institutional business growth.
- Glenmark Life Sciences (GLS): being divested, so future consolidation impact to be considered.
- Overall: Expectation of strong portfolio with multiple approvals, operating leverage, and margin improvements supporting sales and volume growth across markets.
See what Glenmark Pharmaceuticals management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript.
- The company discussed increases in net debt primarily due to payments related to a DOJ settlement and the GLS divestment transaction, not new fundraising.
- Glenmark is focusing on operational performance improvements and margin expansion rather than raising new funds.
- No specific guidance or comments on equity issuance or debt raising were provided during the Q2 FY24 earnings call.
- The management appears confident in cash flow improvements in H2 FY24 from business performance and expects to manage existing obligations without new fundraises.
See what Glenmark Pharmaceuticals management said on order book — free account, 30 seconds.
Capex plans
Yes- Consolidated total asset addition in Q2 FY24 was Rs.249.7 crores, including Rs.162.8 crores in tangible assets and Rs.86.9 crores in intangible assets (Page 7).
- Ongoing investment in Ichnos: Glenmark invested Rs.1,613 million (~US$19.6 million) in Q2 FY24 and Rs.3,030 million (~US$36.8 million) in H1 FY24, focusing on innovation and strategic growth (Page 7).
- No specific new capex guidance mentioned for future quarters, but the company is focusing on operational improvements such as remediation completion at Monroe and market expansions.
- Mention of launching new products and expanding presence in key markets like US (respiratory and injectables), Europe, Latin America, and India suggests continued strategic investments in portfolio and geographic diversification (Pages 9, 12, 13).
- GLS transaction expected to be recognized in Q3 FY24; post-divestment, capital allocation may shift (Page 7).
Track Glenmark Pharmaceuticals — get its next earnings analysis in your feed
How does Glenmark Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Glenmark Pharmaceuticals rank in Pharmaceuticals & Biotechnology?
Compare Glenmark Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Glenmark Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem